Valuation: Steminent Biotherapeutics Inc.

Market Cap 6.26B 197M 172M 162M 147M 276M 18.88B 277M 1.94B 749M 9.6B 739M 723M 30.88B P/E 2024
-8.1x
P/E 2025 -20.4x
Enterprise Value 5.84B 183M 160M 151M 137M 257M 17.59B 258M 1.81B 698M 8.94B 689M 673M 28.78B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
58.85%
Yield 2024 *
-
Yield 2025 -
1 day-3.18%
1 week+26.14%
Current month+97.15%
1 month+90.24%
3 months+82.69%
6 months+70.79%
Current year+152.91%
1 week 108.5
Extreme 108.5
169.5
1 month 74.6
Extreme 74.6
169.5
Current year 51.4
Extreme 51.4
169.5
1 year 37.85
Extreme 37.85
169.5
3 years 15.25
Extreme 15.25
169.5
5 years 15.25
Extreme 15.25
169.5
10 years 15.25
Extreme 15.25
169.5
Manager TitleAgeSince
Chief Executive Officer - 2018-11-25
Director of Finance/CFO - 2021-09-14
Investor Relations Contact - 2023-09-30
Director TitleAgeSince
Director/Board Member 54 2021-12-07
Director/Board Member - 2020-09-14
Chairman - 2024-01-25
Change 5-day change 1-year change 3-year change Capi.($)
-3.18%+26.14%+280.48% - 397M
+0.11%+1.98%-0.04%+9.69% 46.18B
-1.12%+1.78%+40.07%+27.26% 44.35B
-3.04%-6.29%+322.27%+517.36% 42.21B
-0.74%+1.25%+2.32%+67.94% 40.19B
-0.50%-0.77%+11.86%+40.41% 29.83B
-0.46%+4.22%+21.99%+124.21% 17.17B
-0.97%-10.17% - - 15.7B
-0.57%+7.78%+21.76%+38.08% 15.32B
-3.28%-3.07%-8.54%-37.61% 13.09B
Average -1.38%+4.89%+76.91%+98.42% 26.44B
Weighted average by Cap. -1.12%+1.68%+66.48%+119.41%

Financials

2024 2025
Net sales - -
Net income -159M -4.99M -4.35M -4.11M -3.73M -6.99M -479M -7.02M -49.19M -18.98M -243M -18.74M -18.32M -783M -174M -5.47M -4.77M -4.5M -4.09M -7.66M -525M -7.69M -53.93M -20.81M -267M -20.54M -20.08M -858M
Net Debt -153M -4.81M -4.2M -3.96M -3.6M -6.74M -462M -6.77M -47.48M -18.32M -235M -18.08M -17.68M -756M -426M -13.38M -11.67M -11.02M -10M -18.74M -1.28B -18.82M -132M -50.92M -653M -50.26M -49.14M -2.1B
Logo Steminent Biotherapeutics Inc.
Steminent Biotherapeutics Inc is a Taiwan-based trading company mainly engaged in the research and development of new stem cell drugs and the development of allogeneic mesenchymal stem cell technology platforms. The Company's main product is the new stem cell drug product Stemchymal. The new stem cell drug product Stemchymal is used to treat spinocerebellar ataxia, Huntington's disease, acute ischemic stroke, acute inflammatory indications and other diseases.
Employees
-
Date Price Change Volume
26-09-17 NT$152.00 -3.18% 2,800,643
26-09-17 NT$157.00 +14.18% 3,952,993
26-09-16 NT$137.50 +5.77% 2,062,122
26-09-15 NT$130.00 +14.54% 2,035,793
26-09-14 NT$113.50 -0.87% 870,363
  1. Stock Market
  2. Stocks
  3. 7729 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!